Document Detail


Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
MedLine Citation:
PMID:  20014944     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Targeted therapies used in the treatment of metastatic renal cell carcinoma (RCC) are known to have the potential for cardiotoxicity and should be used with caution in patients with cardiac comorbidities. A retrospective review identified two RCC cases treated with sorafenib in the context of preexisting cardiomyopathy. Sorafenib therapy resulted in disease stabilization of progressing RCC for both cases, without worsening of cardiac ejection fraction. Further evaluation of the cardiac safety of sorafenib in patients with cardiomyopathy is warranted.
Authors:
Pratima Kamada; Arkadiusz Z Dudek
Related Documents :
16049384 - Clinical and morphological diagnosis of cardiac al amyloidosis: a review of findings an...
18765314 - Cardiac involvement with lymphoma: a review of the literature.
24310214 - The mystery of the occluded port that allowed blood withdrawal: is it safe to use stand...
15680004 - Long on qt and low on calcium.
19643644 - Urinary tract infection as a single presenting sign of multiple vaginal foreign bodies:...
6854144 - Leiomyoma of the palate.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Cancer investigation     Volume:  28     ISSN:  1532-4192     ISO Abbreviation:  Cancer Invest.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-10     Completed Date:  2010-05-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8307154     Medline TA:  Cancer Invest     Country:  England    
Other Details:
Languages:  eng     Pagination:  501-4     Citation Subset:  IM    
Affiliation:
Department of Oncology, and Transplantation, University of Minnesota, Minneapolis, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Agents / adverse effects*
Benzenesulfonates / adverse effects*
Carcinoma, Renal Cell / complications*,  drug therapy*,  pathology
Female
Heart Diseases / complications*,  physiopathology
Humans
Kidney Neoplasms / complications*,  drug therapy*,  pathology
Male
Middle Aged
Neoplasm Metastasis
Pyridines / adverse effects*
Stroke Volume*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Benzenesulfonates; 0/Pyridines; 0/sorafenib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expression of WISP3 and RhoC Genes at mRNA and Protein Levels in Inflammatory and Noninflammatory Br...
Next Document:  Correlation Between Argyrophilic Nucleolar Organizer Region Staining and Brain Tumor Classification ...